EOM

Iron Bow Joins Peraton in Supporting $2.8B Special Operations Forces IT Enterprise Contract

Retrieved on: 
Tuesday, March 26, 2024
Technology, Contracts, Security, Military, Software, Networks, Government Technology, Data Management, Defense, SIE, Iron, EOM, Air force, Special operations, VTC, USSOCOM, Peraton, Special forces, Government, Navy, Management

Iron Bow Technologies , the next-generation technology solutions provider to government, commercial, and healthcare markets, today announced it has joined Peraton in the implementation of the $2.8 billion Special Operations Forces IT Enterprise Contract (SITEC) 3 Enterprise Operations & Maintenance (EOM) task order.

Key Points: 
  • Iron Bow Technologies , the next-generation technology solutions provider to government, commercial, and healthcare markets, today announced it has joined Peraton in the implementation of the $2.8 billion Special Operations Forces IT Enterprise Contract (SITEC) 3 Enterprise Operations & Maintenance (EOM) task order.
  • This task order aims to deliver advanced IT solutions and network services to the US Special Operations Command (USSOCOM), its Component Commands, Theater Special Operations Commands (TSOCs), deployed forces, CIO/J6, and end-users over an eight-year duration.
  • “Special Operations Forces play a vital role in safeguarding US national security, navigating some of the world’s most demanding environments,” said Rob Watson, Vice President, Sales (Air Force, Navy, and Marines), Iron Bow Technologies.
  • “We’re honored to bring a world-class team of innovators, like Iron Bow, on board to support the USSOCOM mission,” said Tarik Reyes, President, Defense Mission and Health Solutions sector, Peraton.

HyperLight Expands Electro-Optical Modulator Product Line to 110GHz, 65GHz, and 20GHz with Sub-Volt Half-Wave Voltage

Retrieved on: 
Wednesday, March 20, 2024
Technology, Mobile, Wireless, Semiconductor, Engineering, Telecommunications, Nanotechnology, Manufacturing, Internet, Hardware, Conference, EOM, Thorlabs, MX110, TFLN, Modulation, Hertz, Programmable interrupt controller, PIC, Multimedia, Mobile phone

HyperLight, the leading provider of integrated electro-optical modulators (EOMs), is proud to announce the expansion of its intensity modulator series.

Key Points: 
  • HyperLight, the leading provider of integrated electro-optical modulators (EOMs), is proud to announce the expansion of its intensity modulator series.
  • This announcement underscores HyperLight’s continued commitment to cutting edge innovation of photonics integrated circuits (PICs).
  • HyperLight is adding a new low half-wave-voltage (Vπ) 65 GHz Intensity Modulator to its modulator line-up.
  • Concurrently, HyperLight is unveiling the 20 GHz Ultra Low Vπ Intensity Modulator, achieving a groundbreaking Vπ of

United States Order Management Software Market Report 2023: Retailers are Racing to Compete with Amazon and Walmart

Retrieved on: 
Wednesday, November 8, 2023
Sale, OMS, Walmart, Commerce, Research, Growth, COVID-19, EOM, Amazon, POS, Retail, Online shopping

DUBLIN, Nov. 8, 2023 /PRNewswire/ -- The "The Order Management Software Market 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 8, 2023 /PRNewswire/ -- The "The Order Management Software Market 2023" report has been added to ResearchAndMarkets.com's offering.
  • In this report, the publisher looks at how retailers are investing in one enterprise order management system in order to stay competitive.
  • Retailers are racing to compete with Amazon and Walmart.
  • Retail supply chain disruptions, record inflation and a looming global recession are greatly challenging retailers after multiple years of growth.

EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613

Retrieved on: 
Tuesday, November 7, 2023
IND, Glossary, Incidence, Gastrointestinal tract, Patent, Korea Disease Control and Prevention Agency, Fungal infection, Cachexia, Toxicology, OTC, Prevalence, MD, Doctor of Philosophy, Ulcerative colitis, Inflammatory bowel disease, Crohn's disease, CDC, Disease, Clinical trial, COVID-19, Risk, EOM, Effectiveness, IBD, Patent pending, Patient, Pharmaceutical industry, Vaccine, AIDS

MONTVALE, N.J., Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613.

Key Points: 
  • MONTVALE, N.J., Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613.
  • In light of these clinical trial results, the company is currently preparing to initiate an EOM613 clinical program in Crohn's disease.
  • "In previous clinical trials in AIDS, cancer cachexia and COVID-19 patients, EOM613 was demonstrated to be well-tolerated, even in very sick patients.
  • "EOM's priority is to initiate a clinical program in inflammatory bowel disease as soon as possible," added Irach B. Taraporewala, PhD, Chief Executive Officer of EOM.

ZeroSum Market First Report October 2023: New Car Inventory Is Continuing To Rise; Used Vehicles Prices Drop for the Fifth Straight Month

Retrieved on: 
Thursday, October 26, 2023
Cloud, Environment, Market, COVID, Original equipment manufacturer, MSRP, EV, EOM, UAW, MOM, Retail, Gasoline, Fireworks

The Market First report is designed to provide that bigger picture viewpoint and backdrop in which dealer decisions are made.

Key Points: 
  • The Market First report is designed to provide that bigger picture viewpoint and backdrop in which dealer decisions are made.
  • This month's report focuses on a continuing rise in new car inventory, which has been accompanied by a gradual drop in new car pricing as supply has continued to recover.
  • New car prices have dipped to $50,830, a decrease of -1.37% from September EOM, the fifth month in a row that prices have dropped.
  • This is a slight decrease from 2,081,560—which was where inventory sat at the end of September—and used car prices have declined for the fifth month.

American Oncology Network Leaders Slated To Speak at Association for Value-Based Cancer Care 2023 Summit

Retrieved on: 
Wednesday, October 18, 2023
Knowledge, Community Oncology Alliance, Health equity, MD, RN, MBA, Learning, Medicine, EOM, Doctor of Pharmacy, CSSBB, OCN, AON, Intelligence, COA, MHA, Marketplace, Pharmacist, MSN, Management, Nursing, Dispensary, Oncology

“The cancer fight is everyone’s responsibility and so much can be learned by looking to our partners throughout the industry and taking note of best practices.

Key Points: 
  • “The cancer fight is everyone’s responsibility and so much can be learned by looking to our partners throughout the industry and taking note of best practices.
  • Filled with various educational sessions, attendees will gain insightful and relevant information that can be implemented in clinics and institutions.
  • “We are honored to have representatives from AON speaking at this prestigious event,” said Todd Schonherz, AON’s chief executive officer.
  • “To us as an organization, it is important that we consistently work toward being at the forefront of cancer care.

ZeroSum Market First Report September 2023: New Car Inventory Has Reached a New Two-Year High; Used Vehicles Average Price Below $30,000 for the First Time in Two Years

Retrieved on: 
Wednesday, September 27, 2023
News, Gas, Model Y, MSRP, Tesla, EOM, EV, Automotive News, Retail, Gasoline, August

ZeroSum can now report that the average new car price is $51,438, a decrease of -1.17% from August EOM.

Key Points: 
  • ZeroSum can now report that the average new car price is $51,438, a decrease of -1.17% from August EOM.
  • However, used car inventory would have to drop significantly before reaching the 2-year low on inventory from January 2023 (which was 1,510,076.)
  • Along with the slow drop of inventory, used car prices have also continued to decrease for the fourth straight month.
  • September's average EOM used vehicle price is predicted to be $29,471, a difference of -2.31% from August's average price ($30,168.)

EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil

Retrieved on: 
Wednesday, September 6, 2023
Biochemistry, Diabetes, Interleukin, Serum, SC, CASA, COVID-19, Aes, Clinical trial, EOM, IL-6, Brazilian Medical Association, Research, Biomarker, Doctor of Philosophy, Rheumatoid arthritis, Hypertension, Hospital, Cytokine, AIDS, MD, Patient, System, BID, Cachexia, Blood, OTC, ICU, Principal, Safety, Pharmaceutical industry, Vaccine, IL2RA

MONTVALE, N.J., Sept. 6, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc (OTC: IMUC) ("EOM") today announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug product EOM613. The trial was conducted in Brazil.

Key Points: 
  • MONTVALE, N.J., Sept. 6, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc (OTC: IMUC) ("EOM") today announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug product EOM613.
  • The trial was originally designed to enroll a total of 40 patients – 20 in each cohort.
  • The study's topline results indicate that:
    EOM613, administered by subcutaneous (SC) injection was well-tolerated by hospitalized COVID-19 patients.
  • This provides an additional support for EOM's future clinical drug development in various chronic inflammatory diseases," added Irach B. Taraporewala, PhD, CEO of EOM Pharmaceuticals.

ZeroSum Market First Report August 2023: New Car Prices Decline for the First Time in Months, New Car Inventory Approaching Two Million

Retrieved on: 
Friday, August 25, 2023
Cloud, MSRP, EV, Data science, Marketing, Original equipment manufacturer, EOM, Holden Commodore (VP), Blog, COVID, Forecasting, EVS, Traction, Mom, Tesla, Retail, Self storage, Fireworks, Gasoline

In last month's Market First Report, ZeroSum reported that both new and used inventory were declining from earlier in the year.

Key Points: 
  • In last month's Market First Report, ZeroSum reported that both new and used inventory were declining from earlier in the year.
  • Now, a month later, new car inventory is up while used car inventory has continued to decline.
  • ZeroSum predicts that August's end-of-month (EOM) new car inventory will reach 1,965,527.
  • This is an increase from July 2023 EOM (1,881,960) and the highest level that new car inventory has reached since early in the pandemic.

Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy

Retrieved on: 
Sunday, July 30, 2023
FAF, CNV, AMD, Retinal vasculitis, EM, Geographic atrophy, Macular degeneration, EOM, Patient, Physician, Intravitreal administration, Acute posterior multifocal placoid pigment epitheliopathy, Annual general meeting, Webcast, Paratriathlon, Letter, Visual acuity, Safety, Society, ASRS, Choroidal neovascularization, Communications satellite, Pharmaceutical industry, Medical imaging, Dietary supplement, Birth control, ARCHER

BRISBANE, Calif., July 30, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today presented results from the ongoing ARCHER trial in patients with geographic atrophy (GA), underscoring ANX007’s potentially distinct neuroprotective mechanism of action and demonstration of consistent protection from vision loss. Data were presented during an oral presentation titled, “Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration with Intravitreal ANX007: Results of the ARCHER Study,” at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting taking place July 28 – August 1, 2023 in Seattle.

Key Points: 
  • Data were presented during an oral presentation titled, “Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration with Intravitreal ANX007: Results of the ARCHER Study,” at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting taking place July 28 – August 1, 2023 in Seattle.
  • “The results from ARCHER demonstrated dose and time dependent protection of visual function in GA across multiple measures.
  • Annexon conducted additional analyses to further evaluate the effect of ANX007 treatment on BCVA and GA lesion area.
  • The six-month off-treatment follow-up period of the ARCHER trial is ongoing, and Annexon plans to report final results following study conclusion.